MOUNTAIN VIEW, Calif., Feb. 20, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it will report financial results for the fourth quarter and year ended December 31, 2012 after the Nasdaq Market closes on Monday, February 25, 2013. The company will conduct a conference call and an audio webcast at 4:30pm EST the same day.
Date: February 25, 2013 Time: 4:30 PM EST
Listen via Internet: http://ir.vivus.com/U.S. Toll-free: 877-359-2916 Outside U.S.: (+) 224-357-2386 A webcast replay will be available on the VIVUS website for 30 days. About VIVUS VIVUS is a biopharmaceutical company commercializing innovative therapies to address unmet needs in obesity and sexual health for U.S., Europe and other world markets. Qsymia is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. For more information about the company, please visit www.vivus.com . Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2011, and periodic reports filed with the Securities and Exchange Commission.
CONTACT: VIVUS, Inc. Timothy E. Morris Chief Financial Officer email@example.com Financial Media Relations: Joele Frank, Wilkinson Brimmer Katcher Eric Bonach firstname.lastname@example.org 212-355-4449 Investor Relations: The Trout Group Brian Korb email@example.com 646-378-2923
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV